Loading organizations...
§ Private Profile · 2 Trimburgstrasse, Munich, Bavaria 81249, Germany
Kumovis is a company.
Kumovis has raised $4.0M across 1 funding round.
Key people at Kumovis.
Kumovis has raised $4.0M in total across 1 funding round.
Kumovis develops advanced 3D printers specifically for regulated markets, primarily focusing on medical technology. Their systems are engineered to process high-performance polymers, such as PEEK, enabling the reproducible additive manufacturing of critical components. The company's technical approach integrates cleanroom capabilities to ensure high-quality, validated production of medical devices, emphasizing precision and compliance with stringent industry standards.
The company was founded in October 2017 by a team of alumni from the Technical University of Munich, including Stefan Leonhardt, Alexander Henhammer, Stefan Fischer, and Sebastian Pammer. Their insight stemmed from recognizing a significant gap in the market for 3D printing solutions that could meet the rigorous demands of medical applications, particularly the need for reliable processing of specialized materials within controlled environments. This led them to develop technology addressing these unique challenges.
Kumovis's products serve the medical technology sector, providing manufacturers with the ability to produce patient-specific implants and other highly customized medical devices. The company's vision centers on advancing the adoption of additive manufacturing in healthcare, empowering the creation of innovative and personalized medical solutions that meet the highest standards of quality and regulatory approval for improved patient care.
Key people at Kumovis.
Kumovis has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2020 | $4M Series A | — | Ffilipa Venture Capital, High Tech Grunderfonds, Renolit, Solvay Ventures | Announced |
Kumovis has raised $4.0M in total across 1 funding round.
Kumovis's investors include Ffilipa Venture Capital, High-Tech Grunderfonds, Renolit, Solvay Ventures.
Kumovis GmbH is a Munich-based medtech company specializing in 3D printing systems for producing patient-specific medical implants and devices from high-performance polymers like PEEK, PEKK, PPSU, and PLLA.[1][2][3][4] It serves medical device manufacturers, hospitals, and surgeons by enabling decentralized, regulatory-compliant manufacturing of individualized products such as skull implants, spinal probes, and surgical instruments, solving challenges in customization, contamination control, and resource efficiency.[1][2][3][5] The company's flagship product, the Kumovis R1 printer, features an integrated clean-room environment via a unique air filtration system, allowing cost-effective, on-site production with mechanical properties comparable to injection-molded parts; growth includes a Series A funding round led by Renolit and Solvay, a U.S. subsidiary launch, and acquisition by 3D Systems.[1][4][8][10]
Kumovis was founded in 2017 at the Technical University of Munich by five alumni spanning medical, plastics engineering, and related fields, including co-founder and co-director Dr. Ing. Miriam Haerst.[2][3] The idea emerged from research in space and medicine on high-performance plastics, aiming to enable additive manufacturing of plastic implants using established medical polymers that were previously difficult to 3D print with required ductility and sterility.[1][2][6] Early traction came swiftly: in 2018, Kumovis won the Formnext Startup Challenge; by 2019, it launched the R1 printer—the world's first with integrated clean-room technology—backed by High-Tech Gründerfonds investment and later Series A funding.[1][4][9] Pivotal moments include validating the technology with leading hospitals and medtech firms, leading to its 2023 acquisition by 3D Systems.[3][10]
Kumovis rides the wave of personalized medicine and point-of-care manufacturing, where 3D printing decentralizes production to match patient anatomy via DICOM imaging, addressing rising demand for customized implants amid aging populations and complex surgeries.[2][3][5] Timing aligns with maturing additive manufacturing regulations (e.g., FDA pathways for polymers) and post-pandemic supply chain resilience needs, favoring clean-room tech for sterile, on-site fabrication over centralized factories.[4][8] Market forces like high-performance polymer advancements and partnerships (e.g., with Renolit, 3D Systems) amplify its influence, enabling innovations in resorbable implants, drug-delivery devices, and X-ray-visible polymers while pushing ecosystem-wide adoption in orthopedics, neurosurgery, and spine care.[5][6][10]
Post-acquisition by 3D Systems, Kumovis is poised to scale globally via expanded R1 deployments, U.S. operations, and R&D in bioresorbable materials, drug-eluting implants, and optimized workflows for broader applications like shoulder joints and vertebral replacements.[5][8][10] Trends in AI-driven design, sustainable polymers, and hybrid manufacturing will shape its path, potentially revolutionizing surgical outcomes by slashing production times and costs. As a catalyst in medtech's 3D printing shift, its influence will grow through ecosystem collaborations, tying back to its founding vision of empowering decentralized, patient-tailored care.
